CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions

The emergence of CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, has revolutionized the treatment landscape for hormone receptor-positive breast cancer. These agents have demonstrated significant clinical benefits in terms of both progression-free survival and overall survival....

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jin Sun, Hackbart, Hannah, Cui, Xiaojiang, Yuan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380517/
https://www.ncbi.nlm.nih.gov/pubmed/37511548
http://dx.doi.org/10.3390/ijms241411791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380517/
https://www.ncbi.nlm.nih.gov/pubmed/37511548
http://dx.doi.org/10.3390/ijms241411791

Ejemplares similares